• 3M recently reported Q4 2025 results, posting earnings per share of US$1.83 on revenue of US$6.02 billion, while also confirming it would appear at the J.P. Morgan Industrials Conference on March 17, 2026, with a live and archived webcast for investors.
• The combination of an earnings-per-share beat alongside a slight revenue shortfall, plus fresh commentary at a major conference, gives investors new information on how 3M’s operational progress and innovation focus are feeding through to financial performance.
• With 3M’s latest earnings showing higher-than-expected EPS, we’ll examine how this performance update reshapes the company’s existing investment narrative.

Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

3M Investment Narrative Recap

To own 3M today you need to believe that its science‑driven innovation and ongoing efficiency work can offset legal, regulatory and macro headwinds. The Q4 2025 EPS beat, despite a modest revenue miss, mildly supports the near term earnings catalyst but does not materially change the biggest overhang, which remains the uncertainty around PFAS and other litigation costs and their impact on cash flow and profitability.

The most relevant recent announcement here is 3M’s plan to present at the J.P. Morgan Industrials Conference on March 17, 2026, with a live and archived webcast. That appearance gives investors another chance to hear how management sees innovation efforts and operational changes feeding into margins, and whether the latest results alter their tone on risks like ongoing PFAS exposures or slower growth in key end markets.

Yet beneath the reassuring headline numbers, one ongoing legal and regulatory risk that investors should be aware of is ...

3M's narrative projects $26.1 billion revenue and $4.7 billion earnings by 2028.

Uncover how 3M's forecasts yield a $177.32 fair value, a 12% upside to its current price.

Exploring Other Perspectives

This recent EPS beat sits between consensus caution and the more optimistic camp that, before the update, was assuming revenues reach about US$26.9 billion and earnings US$5.1 billion, so it will be important for you to weigh how that faster growth narrative lines up against concerns that 3M’s innovation pace might still lag and potentially leave the company exposed to slower share gains.

Explore 6 other fair value estimates on 3M - why the stock might be worth as much as 38% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your 3M research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free 3M research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 3M's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.